HR Execs on the Move

Scipher Medicine

www.sciphermedicine.com

 
Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kyla Pavlina
 Chief People Officer, Interim Profile
Alison Stowell
 Chief People Officer Profile
Kaliela Osha
 Chief of Staff Profile

Similar Companies

Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.

Atalanta Therapeutics

Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.

Cetac Technologies

Cetac Technologies is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bellen Health Care System

Bellen Health Care System is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.